Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

(Reuters) -The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus ...

The U.S. Food and Drug Administration has approved Moderna’s (NASDAQ:MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

Cambridge: Moderna, Inc. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...

Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...